Advances in mesenchymal to epithelial transition factor signaling pathway and inhibitors.

Author: Jiangjun CAO ¹ ; Zonghui WU ² ; Tingting TONG ³ ; Qingzong ZHU ¹ ; Erhu ZHAO ¹ ; Hongjuan CUI ¹
Author Information

1. State Key Laboratory of Silkworm Genome Biology, College of Biotechnology, Southwest University, Chongqing 400716, China.
2. Hospital of Southwest University, Southwest University, Chongqing 400716, China.
3. College of Animal Science and Technology, Southwest University, Chongqing 400716, China.
Publication Type:Journal Article
Keywords: MET; inhibitors; signal pathway; targeted therapy; the prognosis of cancers
From: Chinese Journal of Biotechnology 2018;34(3):334-351
CountryChina
Language:Chinese
Abstract: As a receptor tyrosine kinase, mesenchymal to epithelial transition factor (MET) is the membrane receptor for hepatocyte growth factor (HGF), which is related with a series of biological functions, such as cell proliferation, progression, apoptosis, metastasis and morphological changes. As research continues, MET is amplified or overexpressed in a wide range of human cancers and closely related with worse prognosis. Therefore, various MET inhibitors are currently being developed as potential treatments for a variety of cancers. Based on our current study we summarize the existing knowledge on structure, biological function and its inhibitors of MET and provide a data phase for future researchers.